
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of Earliest Event Reported): June 6, 2016

CATALYST PHARMACEUTICALS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

Delaware
(State or other jurisdiction
of incorporation)

001-33057
(Commission File
Number)

76-0837053
(I.R.S. Employer
Identification No.)

**355 Alhambra Circle
Suite 1250
Coral Gables, Florida**
(Address of principal executive offices)

33134
(Zip Code)

Registrant's telephone number, including area code: **(305) 420-3200**

Not Applicable
Former Name or Former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.02(e) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

At the Company's 2016 Annual Meeting of Stockholders held on June 6, 2016, Patrick J. McEnany, Philip H. Coelho, Charles B. O'Keeffe, David S. Tierney, Richard J. Daly and Donald A. Denkhous were elected to the Company's Board of Directors to serve until the 2017 Annual Meeting of Stockholders or until their successor is duly elected and qualified, or until their earlier death, resignation or removal.

Item 5.07 Submission of Matters to a Vote of Security Holders

On June 6, 2016, the Company held its Annual Meeting of Stockholders at the Hyatt Regency Coral Gables, 50 Alhambra Plaza, Coral Gables, Florida. The final voting results on the matters considered at the meeting are as follows:

1. Election of Directors:

<u>Name</u>	<u>Votes For</u>	<u>Votes Withheld</u>	<u>Broker Non-Votes</u>
Patrick J. McEnany	36,087,837	2,360,833	27,622,483
Philip H. Coelho	36,091,126	2,357,544	27,622,483
Charles B. O'Keeffe	36,104,101	2,344,569	27,622,483
David S. Tierney	36,091,691	2,356,979	27,622,483
Richard J. Daly	36,093,075	2,355,595	27,622,483
Donald A. Denkhous	36,176,611	2,272,059	27,622,483

2. Approval of an amendment to the Company's 2014 Stock Incentive Plan increasing the shares available for issuance under the plan by 2 million shares:

<u>Votes For</u>	<u>Votes Against</u>	<u>Votes Abstained</u>	<u>Broker Non-Votes</u>
35,554,806	2,837,409	56,455	27,622,483

3. Approval, on an advisory basis, of the compensation of the Company's named executive officers as set forth in its 2016 Annual Meeting Proxy Statement:

<u>Votes For</u>	<u>Votes Against</u>	<u>Votes Abstained</u>	<u>Broker Non-Votes</u>
35,490,462	2,766,382	191,826	27,622,483

4. Ratification of the selection of Grant Thornton, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2016:

<u>Votes For</u>	<u>Votes Against</u>	<u>Votes Abstained</u>
64,936,128	586,747	548,278

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

- 10.1 Amendment No. 1 to the Company's 2014 Stock Incentive Plan (incorporated by reference to Annex A to the Company's 2016 Annual Meeting Proxy Statement dated April 29, 2016)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Catalyst Pharmaceuticals, Inc.

By: /s/ Alicia Grande

Alicia Grande

Vice President, Treasurer and Chief
Financial Officer

Dated: June 7, 2016